Dianne C. Whitfield - 15 Mar 2024 Form 4 Insider Report for Tarsus Pharmaceuticals, Inc. (TARS)

Role
Chief Human Resources Officer
Signature
/s/ Jeffrey Farrow, Attorney-in-Fact
Issuer symbol
TARS
Transactions as of
15 Mar 2024
Net transactions value
-$132,008
Form type
4
Filing time
19 Mar 2024, 19:04:16 UTC
Previous filing
11 Mar 2024
Next filing
07 Mar 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TARS Common Stock Options Exercise +11,711 +44% 38,495 15 Mar 2024 Direct F1
transaction TARS Common Stock Sale $132,008 -4,314 -11% $30.60 34,181 18 Mar 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TARS Restricted Stock Units Options Exercise $0 -4,463 -33% $0.000000 8,925 15 Mar 2024 Common Stock 4,463 Direct F3, F4
transaction TARS Restricted Stock Units Options Exercise $0 -7,248 -25% $0.000000 21,745 15 Mar 2024 Common Stock 7,248 Direct F3, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs").
F2 The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
F3 Each RSU represents a contingent right to receive one share of the Issuer's common stock.
F4 RSUs granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. The RSUs will vest in equal installments on March 15, 2023, March 15, 2024, March 15, 2025 and March 15, 2026, subject to the Reporting Person's continuous service.
F5 RSUs granted on March 8, 2023, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. The RSUs will vest in equal installments on March 15, 2024, March 15, 2025, March 15, 2026 and March 15, 2027, subject to the Reporting Person's continuous service.